C
China Immunotech
Focusing on developing and commercializing the products of cellular immunotherapy for cancer and other diseases
About China Immunotech
China Immunotech is a pioneering biotechnology company specializing in the development of advanced immunotherapy solutions for cancer treatment. The company operates primarily in the biopharmaceutical sector, focusing on creating innovative antigen receptor complexes that enhance the effectiveness of T cell therapies while minimizing side effects. By leveraging its proprietary STAR T and TCR T platforms, China Immunotech targets both viral and solid tumors, aiming to improve patient outcomes and reduce the likelihood of tumor recurrence.
Read full description
China Immunotech serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. The company operates in the highly competitive and rapidly evolving market of cancer immunotherapy. Its business model revolves around the development, clinical testing, and commercialization of its proprietary technologies. Revenue is generated through a combination of product sales, licensing agreements, and partnerships with other entities in the healthcare and pharmaceutical industries.
The company has garnered significant recognition and financial backing, having secured RMB 45 million in Series A financing led by Jianxin Capital, with additional investments from Grower Venture Capital and Zhejiang Huacheng Group. This funding supports the ongoing development and commercialization of its innovative therapies.
At a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Dongcheng District, China
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 25.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning China Immunotech.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jul 2026 | $28M | $206M | Loyal Valley Capital · Fudan Science & Technology Venture Capital | ↗ |
| SERIES BOther financing | Jul 2022 | $41M | $165M | Hetang Venture Capital Management (Beijing) · Hankang Capital · TH Capital (THC) | ↗ |
Growth signals
Latest recorded traffic for China Immunotech is 730 monthly website visits, down 9.9% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
- JCJianxin Capital
- GCGrower Venture Capital
- HGHuacheng Group
TH Capital (THC)- H(Hetang Venture Capital Management (Beijing)
Hankang Capital
Series B and later2 investors entered at this stage
Loyal Valley Capital- FCFudan Science & Technology Venture Capital
Other known investors1 additional known investor
Peking University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about China Immunotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See China Immunotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.